21 September, Bangkok, Thailand – A highly drug resistant malaria "superbug" from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine — Vietnam’s national first-line malaria treatment, leading malaria scientists warn.
The spread of this dominant artemisinin drug resistant P falciparum C580Y mutant malaria parasite lineage across the entire Mekong Sub-region is a serious threat to malaria control and eradication efforts, the scientists say in a letter published today in The Lancet Infectious Diseases.
"A single mutant strain of very drug resistant malaria has now spread from western Cambodia to north-eastern Thailand, southern Laos and into southern Vietnam and caused a large increase in treatment failure of patients with malaria," says letter co-author Oxford Prof. Arjen Dondorp, Head of Malaria and Deputy Head of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Thailand, Asia.
“This could result in an important increase in malaria transmission in these countries and severely jeopardize their malaria elimination efforts,” said Prof. Dondorp. “We hope this evidence will be used to reemphasize the urgency of malaria elimination in the Mekong sub-region before falciparum malaria becomes close to untreatable.”
The spread of artemisinin resistance in Plasmodium falciparum and the subsequent loss of partner antimalarial drugs in the Greater Mekong sub-region presents one of the greatest threats to the control and elimination of malaria, the letter authors say.
“We are losing a dangerous race. The spread of this malaria “superbug” has caused an alarming rise in treatment failures forcing changes in drug policy and leaving few options for the future,” said said letter co-author and Mahidol and Oxford University Prof Sir Nicholas White. “We need to tackle this public health emergency urgently.”
Michael Chew from Wellcome's Infection and Immunobiology team said: "The spread of this malaria "superbug" strain, resistant to the most effective drug we have, is alarming and has major implications for public health globally. Around 700,000 people a year die from drug-resistant infections, including malaria. If nothing is done, this could increase to millions of people every year by 2050. Efforts to help track resistance to drugs are vital for improving diagnosis, treatment, and control of drug resistant infections."
Press enquiries and interview requests:
ASIA: Kindly contact John Bleho, Media and Communications (MORU)
Mobile / WhatsApp / Facetime: +66.81.750.0539 www.tropmedres.ac
UK, EUROPE, AFRICA & AMERICAS media desks: please contact:
Barney McManigal, email@example.com
Hannah Isom, H.Isom@wellcome.ac.uk
Imwong M, Hien TT, Thuy-Nhien N, White NJ, Dondorp AM. Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Published online 23:30 GMT 20 September 2017 in the Lancet Infectious Diseases, 17TLID1086 Vol 17 Oct 2017 issue.
Signatory details and additional references:
The letter was signed by Wellcome Trust-supported researchers at the Faculty of Tropical Medicine, Mahidol University and the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand; the Oxford University Clinical Research Unit (OUCRU) in Ho Chi Minh City, Vietnam; and the Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, UK.
Ashley EA, Dhorda M, Fairhurst RM, et al. Tracking Resistance to Artemisinin Collaboration (TRAC). Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 371: 411–23.
Imwong M, Suwannasin K, Kunasol C, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong Subregion: a molecular epidemiology observational study. Lancet Infect Dis 2017; 17: 491–97.
World Health Organization. Status report on artemisinin and ACT resistance (April 2017).
Thanh NV, Thuy-Nhien N, Tuyen NT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J 2017; 16: e27.